
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Here: a quiz about treating oral candidiasis with an azole drug in an HIV-positive person.
When oral candidiasis develops in a person with HIV infection, therapy with an azole drug will be most effective if the underlying pathogen is:






